Valuation : Zymeworks Inc.

Market Cap 2.07B 1.78B 1.68B 1.53B 2.87B 196B 2.87B 19.82B 7.69B 100B 7.78B 7.61B 323B P/E 2026 *
21.3x
P/E 2027 * 36.2x
Enterprise Value 2.07B 1.78B 1.68B 1.53B 2.87B 196B 2.87B 19.82B 7.69B 100B 7.78B 7.61B 323B EV / Sales 2026 *
6.81x
EV / Sales 2027 * 5.86x
Free-Float
92.08%
Yield 2026 *
-
Yield 2027 * -
1 day-2.37%
1 week+3.25%
Current month-0.75%
1 month+24.21%
3 months+21.42%
6 months+17.70%
Current year+10.86%
1 week 27.81
Extreme 27.81
31.34
1 month 23.18
Extreme 23.18
31.34
Current year 21.52
Extreme 21.52
31.34
1 year 14.69
Extreme 14.69
31.34
3 years 6.02
Extreme 6.015
31.34
5 years 4.11
Extreme 4.11
37.19
10 years 4.11
Extreme 4.11
59.03
Manager TitleAgeSince
Chief Executive Officer 63 2022-01-04
Director of Finance/CFO 44 2026-03-31
Chief Tech/Sci/R&D Officer - 2024-11-30
Director TitleAgeSince
Chairman 63 2022-01-04
Director/Board Member 61 2019-05-31
Director/Board Member 52 2020-02-29
Date Insider Type Main position Quantity % Market Cap. Importance
7/6/26 Free

Chief Operating Officer

939 0.0013%
5/13/26 Free

EVP, General Counsel

297,000 0.4027%
5/13/26 Other

EVP, General Counsel

0 0% -
Change 5-day change 1-year change 3-year change Capi.($)
-2.37%+3.25%+93.95%+298.23% 2.07B
-1.79%-2.27%+43.23%+88.96% 67.98B
-2.06%-0.18%+39.67%+86.44% 64.94B
-0.31%+6.54%-12.96%+378.92% 27.58B
-3.00%-2.90%+33.13%+12.54% 25.74B
+0.86%+1.65%-7.74%-14.95% 26.06B
-1.46%+0.42%+23.61%-18.61% 20.09B
-2.96%-15.21%+216.20%+368.10% 17.16B
-1.49%-4.88%-6.60%+531.89% 14.92B
-0.20%+8.37%+55.78%+164.98% 14.62B
Average -1.48%+0.56%+47.83%+189.65% 28.12B
Weighted average by Cap. -1.53%+0.20%+38.78%+138.53%

Financials

2026 *2027 *
Net sales 304M 262M 246M 225M 421M 28.71B 422M 2.91B 1.13B 14.73B 1.14B 1.12B 47.45B 353M 304M 286M 261M 489M 33.37B 490M 3.38B 1.31B 17.12B 1.33B 1.3B 55.15B
Net income 121M 104M 98.19M 89.7M 168M 11.45B 168M 1.16B 450M 5.88B 455M 445M 18.93B 88.98M 76.57M 72.04M 65.81M 123M 8.4B 123M 851M 330M 4.31B 334M 327M 13.89B
Net Debt - -
Logo Zymeworks Inc.
Zymeworks Inc. is a biotechnology company. The Company is engaged in managing a portfolio of healthcare assets and developing a pipeline of multifunctional biotherapeutics to improve the standard of care for conditions, including cancer, inflammation, and autoimmune disease. Its antibody-drug conjugates (ADCs) include ZW191, ZW251, and ZW220. ZW191 is a clinical-stage ADC that targets folate receptor alpha-expressing tumors including ovarian cancer, endometrial cancer, and non-small cell lung cancer (NSCLC), which is built using bystander-active, TOPO1i payload technology, ZD06519. ZW251 is a clinical-stage ADC molecule designed for the treatment of glypican 3 (GPC3)-expressing hepatocellular carcinoma (HCC). ZW220 is an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer, built using bystander active TOPO1i payload technology, ZD06519. Its therapeutic platforms can be used to develop multifunctional fit-for-purpose biotherapeutics with bispecific capabilities.
Employees
231
Date Price Change Volume
26-09-04 US$29.19 -2.37% 476,599
26-09-03 US$29.90 -3.70% 790,935
26-09-02 US$31.05 +4.65% 808,098
26-09-01 US$29.67 +0.88% 483,063
26-08-31 US$29.41 +4.03% 716,494
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
29.19USD
Average target price
41.75USD
Spread / Average Target
+43.03%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ZYME Stock